![]() While no one oral contraceptive formulation is likely to be the optimum choice for all women, NOMAC-E2 is a formulation with effectiveness comparable with that of other oral contraceptives, and a reassuring safety profile. ![]() Preliminary studies suggest that NOMAC-E2 does not seem to have negative effects on hemostatic and metabolic parameters. The most common adverse events were irregular bleeding, acne, and weight gain. Few severe adverse events were reported in the randomized controlled trials. The adverse event profile appears to be acceptable. The bleeding pattern on NOMAC-E2 is characterized by fewer bleeding/spotting days, shorter withdrawal bleeds, and a higher incidence of amenorrhea than the comparator oral contraceptive containing drospirenone and ethinyl estradiol. Two recently published randomized controlled trials demonstrate that NOMAC-E2 is an effective contraceptive, with a Pearl Index less than one pregnancy per 100 woman-years. Estradiol, though it has a lower bioavailability, has been successfully combined with NOMAC in a monophasic oral contraceptive. NOMAC is a progestin derived from testosterone, which has high bioavailability, rapid absorption, and a long half-life. The approved dosing regimen is 24 days of active hormone, followed by a 4-day hormone-free interval. ![]() The oral contraceptive NOMAC-E2 contains nomegestrol acetate (NOMAC) 2.5 mg + 17b-estradiol (E2) 1.5 mg. List Randomizer This form allows you to arrange the items of a list in random order. Concerns about the risk of venous thromboembolism continue to drive the search for the safest oral contraceptive formulations. While safe and effective for many women, the failure rate of oral contraception is about 8%. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from.Johns Hopkins University School of Medicine, Baltimore, MD, USAĪbstract: Oral contraceptives remain a popular method of contraception over 50 years after their introduction. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. This functionality is provided solely for your convenience and is in no way intended to replace human translation. You have requested "on-the-fly" machine translation of selected content from our databases. you will need A Windows Computer (No Macs) A stable and good/fast internet connection A Samsung. The adverse event profile appears to be acceptable. Random Word Generator: Generate a list of random words. ![]() The oral contraceptive NOMAC-E2 contains nomegestrol acetate (NOMAC) 2.5 mg + 17b-estradiol (E2) 1.5 mg. Oral contraceptives remain a popular method of contraception over 50 years after their introduction. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |